Patient reported outcomes (PROS) in psoriasis patients
Marron, S.E. ; Cerro-Muñoz, P.A. ; Palma-Ruiz, A.M. ; Simal-Gil, E. (Universidad de Zaragoza) ; Garcia-Felipe, R. (Universidad de Zaragoza) ; Porta-Aznarez, N. (Universidad de Zaragoza) ; Martin-Marco, R. ; Baldellou-Lasierra, R. ; Gilaberte-Calzada, Y. (Universidad de Zaragoza) ; Alcalde-Herrero, V.M. ; Fuentelsaz del Barrio, M.V. ; Garcia-Latasa de Aranibar, F.J. (Universidad de Zaragoza) ; Alvarez-Salafranca, M. (Universidad de Zaragoza) ; Tomas-Aragones, L. (Universidad de Zaragoza)
Resumen: P20
Introduction: Psoriasis is a chronic skin disease with negative physical, mental and social manifestations. Method: We carried out a longitudinal and prospective study under routine clinical practice conditions. The objective of the study was to measure quality of life with the Short Form-36 Survey (SF-36) and correlate the results with clinical variables using the PASI and BSA in a group of 17 patients with moderate to severe psoriasis treated with Ustekinumab. Results: In the baseline evaluation we observed the following results: 35.3% reported physical malfunction, 64.7% debilitating pain, 82.3% poor health in general, 76.4% bad vitality, 88.2% social malfunction, 100% emotional malfunction and 82.3% poor mental health. At week 78 we observed the following results: 41.15% reported very good physical functioning, 76.1% no pain, 58.8% good general health, 58.8% very good vitality, 70%, 5% good social functioning, 70.5% good emotional functioning and 52.9% good mental health. Conclusion: We observed that the perception of patients with moderate-severe psoriasis regarding their health at the beginning of treatment with Ustekinumab was poor and that they experienced a significant improvement throughout the successive weeks of treatment.
Idioma: Inglés
Año: 2019
Publicado en: ACTA DERMATO-VENEREOLOGICA 99, 8 (2019), 752
ISSN: 0001-5555
Originalmente disponible en: Texto completo de la revista
Factor impacto JCR: 4.016 (2019)
Categ. JCR: DERMATOLOGY rank: 7 / 68 = 0.103 (2019) - Q1 - T1
Factor impacto SCIMAGO: 1.01 - Medicine (miscellaneous) (Q1) - Dermatology (Q1)
Tipo y forma: Congress (Published version)
Área (Departamento): Área Psicolog.Evolut.Educac (Dpto. Psicología y Sociología)
Área (Departamento): Área Dermatología (Dpto. Medicina, Psiqu. y Derm.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes.
Exportado de SIDERAL (2021-01-28-12:42:48)
Visitas y descargas
Introduction: Psoriasis is a chronic skin disease with negative physical, mental and social manifestations. Method: We carried out a longitudinal and prospective study under routine clinical practice conditions. The objective of the study was to measure quality of life with the Short Form-36 Survey (SF-36) and correlate the results with clinical variables using the PASI and BSA in a group of 17 patients with moderate to severe psoriasis treated with Ustekinumab. Results: In the baseline evaluation we observed the following results: 35.3% reported physical malfunction, 64.7% debilitating pain, 82.3% poor health in general, 76.4% bad vitality, 88.2% social malfunction, 100% emotional malfunction and 82.3% poor mental health. At week 78 we observed the following results: 41.15% reported very good physical functioning, 76.1% no pain, 58.8% good general health, 58.8% very good vitality, 70%, 5% good social functioning, 70.5% good emotional functioning and 52.9% good mental health. Conclusion: We observed that the perception of patients with moderate-severe psoriasis regarding their health at the beginning of treatment with Ustekinumab was poor and that they experienced a significant improvement throughout the successive weeks of treatment.
Idioma: Inglés
Año: 2019
Publicado en: ACTA DERMATO-VENEREOLOGICA 99, 8 (2019), 752
ISSN: 0001-5555
Originalmente disponible en: Texto completo de la revista
Factor impacto JCR: 4.016 (2019)
Categ. JCR: DERMATOLOGY rank: 7 / 68 = 0.103 (2019) - Q1 - T1
Factor impacto SCIMAGO: 1.01 - Medicine (miscellaneous) (Q1) - Dermatology (Q1)
Tipo y forma: Congress (Published version)
Área (Departamento): Área Psicolog.Evolut.Educac (Dpto. Psicología y Sociología)
Área (Departamento): Área Dermatología (Dpto. Medicina, Psiqu. y Derm.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. Exportado de SIDERAL (2021-01-28-12:42:48)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Articles > Artículos por área > Psicología Evolutiva y de la Educación
Articles > Artículos por área > Dermatología
Record created 2021-01-28, last modified 2021-01-28